JP2013503184A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503184A5
JP2013503184A5 JP2012527002A JP2012527002A JP2013503184A5 JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5 JP 2012527002 A JP2012527002 A JP 2012527002A JP 2012527002 A JP2012527002 A JP 2012527002A JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5
Authority
JP
Japan
Prior art keywords
seq
cancer
antibody
antigen
mip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527002A
Other languages
English (en)
Japanese (ja)
Other versions
JP5740772B2 (ja
JP2013503184A (ja
Filing date
Publication date
Priority claimed from US12/644,146 external-priority patent/US7981398B2/en
Priority claimed from US12/731,781 external-priority patent/US8003111B2/en
Priority claimed from US12/752,649 external-priority patent/US8034352B2/en
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed filed Critical
Priority claimed from PCT/US2010/046889 external-priority patent/WO2011025904A1/en
Publication of JP2013503184A publication Critical patent/JP2013503184A/ja
Publication of JP2013503184A5 publication Critical patent/JP2013503184A5/ja
Publication of JP5740772B2 publication Critical patent/JP5740772B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527002A 2009-08-31 2010-08-27 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 Active JP5740772B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US23842409P 2009-08-31 2009-08-31
US61/238,424 2009-08-31
US12/644,146 US7981398B2 (en) 2005-04-06 2009-12-22 PEGylation by the dock and lock (DNL) technique
US12/644,146 2009-12-22
US12/731,781 US8003111B2 (en) 2005-04-06 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/731,781 2010-03-25
US12/752,649 2010-04-01
US12/752,649 US8034352B2 (en) 2005-04-06 2010-04-01 Tetrameric cytokines with improved biological activity
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,140 2010-04-05
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
PCT/US2010/046889 WO2011025904A1 (en) 2009-08-31 2010-08-27 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015080993A Division JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用

Publications (3)

Publication Number Publication Date
JP2013503184A JP2013503184A (ja) 2013-01-31
JP2013503184A5 true JP2013503184A5 (cg-RX-API-DMAC10.html) 2013-09-19
JP5740772B2 JP5740772B2 (ja) 2015-07-01

Family

ID=43628394

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012527002A Active JP5740772B2 (ja) 2009-08-31 2010-08-27 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用
JP2015080993A Expired - Fee Related JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015080993A Expired - Fee Related JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用

Country Status (7)

Country Link
EP (1) EP2473186A4 (cg-RX-API-DMAC10.html)
JP (2) JP5740772B2 (cg-RX-API-DMAC10.html)
CN (1) CN102481348A (cg-RX-API-DMAC10.html)
AU (1) AU2010286642B2 (cg-RX-API-DMAC10.html)
CA (1) CA2772572A1 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01331A (cg-RX-API-DMAC10.html)
WO (1) WO2011025904A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
EP2473187A4 (en) * 2009-08-31 2015-09-16 Immunomedics Inc COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
EP2552483A4 (en) * 2010-04-01 2013-09-25 Immunomedics Inc USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS
JP6205621B2 (ja) * 2012-01-26 2017-10-04 アイビーシー ファーマスーティカルズ,インコーポレイテッド 抗体を有するインターフェロンλでの標的化は抗腫瘍および抗ウイルス活性を大きく増強する
WO2014006225A1 (en) * 2012-07-06 2014-01-09 Innovative Technologies In Biological Systems S.L. Fluorescent fusion polypeptide, biosensor comprising said polypeptide and uses thereof
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
ES2984656T3 (es) * 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2019285048B2 (en) * 2018-06-13 2023-06-08 The Scripps Research Institute Nanoparticle vaccines with novel structural components
CA3163358A1 (en) * 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
CA2484676A1 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
CA2497254A1 (en) * 2002-09-06 2004-03-18 Forschungsverbund Berlin E. V. Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
CN101171034B (zh) * 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物

Similar Documents

Publication Publication Date Title
JP2016513098A5 (cg-RX-API-DMAC10.html)
US10385139B2 (en) Murine, chimeric, humanized or human anti-TNF-alpha antibodies
US8282934B2 (en) Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP2271364B1 (en) Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
FI3903829T3 (fi) Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja
US9498542B2 (en) Tetrameric cytokines with improved biological activity
AU2013302696B2 (en) T-cell redirecting bispecific antibodies for treatment of disease
AU2010286642B2 (en) Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof
JP2016520548A5 (cg-RX-API-DMAC10.html)
JP2014514345A5 (cg-RX-API-DMAC10.html)
US20110020273A1 (en) Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US9931413B2 (en) Tetrameric cytokines with improved biological activity
CN105566498A (zh) 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途